Science advice: The firing of
drug policy adviser David Nutt has led to a row in the United Kingdom about how the government should handle independent scientific advice.
U.K. Science Minister Lord Paul Drayson is the latest notable to condemn the sacking of David Nutt, former top
drug policy adviser to the British government.
Not exact matches
John Ehrlichman, Nixon's domestic
policy adviser, later confessed to Dan Baum, author of another trenchant study of
drugs, Smoke and Mirrors (1996), that Nixon's election team was looking for scapegoats.
His proposals for more rational, evidence - based
drug policies have triggered angry reactions, and he was fired as a top U.K. government
adviser in 2009 for criticizing a new cannabis
policy.
But as demonstrated in Kai Kupferschmidt's News Focus profile of David Nutt, a neuropsychopharmacologist at Imperial College London and an
adviser to the British government on
drug policy, combining the two roles can make sense when it's done right.
Signatories of the letter include David King and Robert May, former government chief scientific
advisers; Colin Blakemore, a member of the U.K.
Drug Policy Commission and former director of the Medical Research Council; and Gabriel Horn, chair of the Academy of Medical Sciences Working Group on Brain Science, Addiction and
Drugs.
Clinical trials that involve new molecular entities occur all the time, says R. Alta Charo, a bioethicist at the University of Wisconsin Law School in Madison and a former
policy adviser to the US Food and
Drug Administration.
The work of the committee will be managed on a daily basis by a special
adviser to Mr. Gonzalez, Jill Harris, who has spent her career working for criminal justice reform at groups like the American Civil Liberties Union and the
Drug Policy Alliance.